171 related articles for article (PubMed ID: 37700010)
1. Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients.
Lee RH; Curtis J; Drake MT; Bobo Tanner S; Lenert L; Schmader K; Pieper C; North R; Lyles KW
Osteoporos Int; 2024 Jan; 35(1):181-187. PubMed ID: 37700010
[TBL] [Abstract][Full Text] [Related]
2. Association between bisphosphonate use and COVID-19 related outcomes.
Thompson J; Wang Y; Dreischulte T; Barreiro O; Gonzalez RJ; Hanč P; Matysiak C; Neely HR; Rottenkolber M; Haskell T; Endres S; von Andrian UH
Elife; 2023 Aug; 12():. PubMed ID: 37534876
[TBL] [Abstract][Full Text] [Related]
3. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Henk HJ; Kaura S; Teitelbaum A
J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
[TBL] [Abstract][Full Text] [Related]
5. Denosumab and Mortality in a Real-World Setting: A Comparative Study.
Alarkawi D; Tran T; Chen W; March LM; Blyth FM; Blank RD; Bliuc D; Center JR
J Bone Miner Res; 2023 Dec; 38(12):1757-1770. PubMed ID: 37915252
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
[TBL] [Abstract][Full Text] [Related]
7. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
[TBL] [Abstract][Full Text] [Related]
8. Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.
Hokugo A; Kanayama K; Sun S; Morinaga K; Sun Y; Wu Q; Sasaki H; Okawa H; Evans C; Ebetino FH; Lundy MW; Sadrerafi K; McKenna CE; Nishimura I
Bone; 2019 Jun; 123():115-128. PubMed ID: 30926440
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
10. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
16. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
18. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
Oryan A; Sahvieh S
Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
[TBL] [Abstract][Full Text] [Related]
19. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
